文献速递前列腺增生与排尿功能障碍

碱化利多卡因作为onabotulinumtoxinA注射前麻醉的随机试验

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial.
PubMed 文献 · BJU Int · 2025-01-11

这项单中心、随机、双盲、安慰剂对照两周期交叉试验纳入50例计划接受BTX-A注射的女性,比较膀胱内碱化利多卡因与安慰剂对操作疼痛的影响。结果显示碱化利多卡因组平均VAS评分21.3 mm,显著低于安慰剂组的41.6 mm,平均差异-20.3 mm(95%CI -29.2至-11.5 mm;P<0.001);不良事件和患者满意度两组无显著差异。

要点

  • 碱化利多卡因组平均VAS疼痛评分21.3 mm,安慰剂组41.6 mm,平均差异-20.3 mm(P<0.001)。
  • 不良事件(P=0.825)和患者满意度(P=0.138)在两组间无显著差异。
  • 50例入组患者中41例纳入符合方案分析。

核心结论

  • 膀胱内滴注碱化利多卡因在BTX-A注射前可显著降低VAS疼痛评分,与安慰剂相比平均差异为-20.3 mm(95%CI -29.2至-11.5 mm;P<0.001)。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照两周期交叉试验,于2022年9月至2024年5月在本院门诊泌尿妇科诊所纳入计划接受BTX-A注射的女性。
  • 患者按1:1随机分配至第一治疗周期接受碱化利多卡因或安慰剂,第二周期接受替代干预。
  • 碱化利多卡因溶液由盐酸利多卡因(20 mg/mL,20 mL)、碳酸氢钠(1 mmoL/mL,10 mL)和氯化钠(9 g/L,10 mL)组成;匹配安慰剂为氯化钠(9 g/L,40 mL)。
  • 共入组50例患者,其中41例纳入符合方案分析。

主要发现

  • 碱化利多卡因组平均VAS评分为21.3 mm(95%CI 14.7-27.8 mm),安慰剂组为41.6 mm(95%CI 35.0-48.1 mm),平均差异-20.3 mm(95%CI -29.2至-11.5 mm;P<0.001)。
  • 不良事件在碱化利多卡因组与安慰剂组之间无显著差异(P=0.825)。
  • 患者满意度(5分制)在碱化利多卡因组与安慰剂组之间无显著差异(P=0.138)。

关键数值与推荐

  • 主要结局为操作疼痛,采用100 mm视觉模拟量表(VAS)评估。
  • 次要结局包括不良事件(需导尿的排尿后残余尿量、尿路感染、治疗后1周血尿)和患者满意度(5分制)。

临床怎么用

  • 原文结论为BTX-A注射前膀胱内滴注碱化利多卡因与安慰剂相比可显著降低VAS疼痛评分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX-A) injections for overactive bladder. PATIENTS AND METHODS: This single-centre, randomised, double-blind, placebo-controlled two period crossover trial was conducted on women scheduled for BTX-A injections at our outpatient urogynaecology clinic between September 2022 and May 2024. Patients were randomly assigned (1:1) to receive either alkalinised lidocaine or placebo during the first treatment period. Alkalinised lidocaine solution comprised lidocaine hydrochloride (20 mg/mL, 20 mL), sodium hydrogen carbonate (1 mmoL/mL, 10 mL), and sodium chloride (9 g/L, 10 mL). The matching placebo was sodium chloride (9 g/L, 40 mL). The primary outcome measure was procedural pain rated on a 100-mm visual analogue scale (VAS). Secondary outcomes included adverse effects such as post-void residual urine volumes requiring catheterisation, urinary tract infection, haematuria 1 week after treatment, and patient satisfaction measured on a 5-point scale. During the second treatment period, patients received the alternative intervention. RESULTS: We enrolled 50 patients, of which 41 were eligible for per-protocol analyses. The mean VAS score was significantly lower following intravesical alkalinised lidocaine (mean 21.3 mm, 95% confidence interval [CI] 14.7-27.8 mm) compared to placebo (mean 41.6 mm, 95% CI 35.0-48.1 mm) with a mean difference of -20.3 mm (95% CI -29.2 to -11.5 mm; P < 0.001). Adverse events and patient satisfaction did not significantly differ between the alkalinised lidocaine and placebo treatments (P = 0.825 and P = 0.138, respectively). CONCLUSIONS: Intravesical instillation of alkalinised lidocaine before BTX-A injections significantly reduced VAS pain scores compared to placebo (ClinicalTrials.gov identifier: NCT05415865).

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. El Issaoui M, Elmelund M, Klarskov N, et al. Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial. BJU Int. 2025. PMID: 39797697. doi:10.1111/bju.16647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。